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Bacteriophages are viruses that only infect bacterial cells and can be used to treat antibiotic resistant bacterial infections. This study 
focused on the isolation and characterization of bacteriophages lytic to Staphylococcus aureus at Coastal Carolina University (CCU) in 
Conway, South Carolina, as a means to isolate bacteriophages that can potentially be used to treat methicillin-resistant Staphylococcus 
aureus (MRSA), an antibiotic-resistant S. aureus variant. From 2014 to 2018, collection of ear and nose samples from 225 randomly 
selected CCU volunteers was conducted. Filter sterilization, amplification, microbial tests, and PCR analyses were performed in order 
to identify and characterize bacteriophages. Coliphage populations were also monitored as an indicator of temporal competition and 
fecal contamination. A pilot study was initiated in 2017 in which 15 CCU volunteers were sampled once a month from October 2017 
through March 2018 in order to investigate coliphage and S. aureus phage population dynamics. The purpose of this study was to gain 
insight into the lytic Staphylococcus aureus phage repository found in the CCU community, and to explore S. aureus phage dynamics 
amongst the CCU populace. Results indicated that a considerable S. aureus and E. coli phage reservoir exists amongst the CCU 
population. Most phages could not be characterized via PCR analysis, suggesting high diversity. The preliminary study indicated that S. 
aureus and E. coli hosts potentially exhibit temporal competition, of which might be explanatory of phage population fluctuations.  
Introduction 
 
       Bacteriophages are viruses that only infect bacterial cells [1]. Also 
known as phages, these viruses are the most abundant semiautonomous 
genetic agents in the biosphere, making up between 1030 and 1032 
particles on Earth [2]. As the most ubiquitous living entity on the planet, 
bacteriophages play a key role in regulating the microbial balance in 
every ecosystem previously thus far explored [3]. Primarily killing 
bacteria during lytic cycles, bacteriophages lyse their hosts by inserting 
their genomic material into the bacterium, hijacking the available host 
machinery, and using the bacterium’s apparatus to synthesize new phage 
particles. The host cell then lysis and releases new phage particles 
capable of destroying bacteria of the same strain. Such high specificity in 
host selection has made phage therapy a popular topic of research in 
Russia and various Eastern European countries since its co-discovery in 
1915 and 1917 by Frederick Twort and Felix d’Herelle, respectively. 
This geographical seclusion in phage therapy research and application, in 
turn, can mainly be attributed to the discovery of antibiotic “miracle 
drugs” such as penicillin in the 1940s, of which became the focal point 
of antimicrobial research for a number of decades in most of the Western 
world. Analogously, phage therapy has been ignored in much of the 
twentieth century by the West due to poor predictability of phage therapy 
trial results and outcomes attributable to an alluvion of causes, including 
contamination, phage-bacteria specificity, horizontal toxin transfer 
amongst temperate phages, antigenicity of the host immune system, and 
bacterial coevolution [4]. 
      Nevertheless, hundreds of successful phage therapy preclinical 
studies in both animals and humans continued to be conducted in Eastern 
Europe and the former Soviet Union. Worldwide phage research became 
predominantly centered at the Eliava Institute of Bacteriophage, 
Microbiology, and Virology in Tbilisi, Georgia, and the Hirszfeld 
Institute of Immunology and Experimental Therapy in Wroclaw, Poland 
[2]. Numerous phage therapy trials, such as the famous 1960s Georgian 
study illustrating a 3.8-fold decrease in dysentery incidence in 30,769 
children administered a cocktail of bacteriophages over a 109-day period 
[5], gave rise to a preference of bacteriophage administration to 
antibiotic treatment in select Eastern European countries, as is 
epitomized by the numerous commercial phage preparations sold in 
Russian and Georgian pharmacies and transported to Western European 
countries as a “last resort” treatment option [2]. Whilst many scientists in 
the Western sphere deemed Eastern European phage studies to be 
dubitable in outcome due to limited study control measures, the 
monumental amount of benefits attributed to the usage of bacteriophage 
therapy, as excavated and delineated by twentieth-century Eastern 
European studies, was recently corroborated and ascertained by several 
experiments in both the United States and United Kingdom, as reviewed 
by J. Alisky, et al. [6]. Phages are the natural products crafted by billions 
of years of evolution as highly specialized deliverers of diverse 
bactericidal agents targeting bacterial cytoplasmic contents. The benefits 
of bacteriophage therapy can thus be framed in terms of the biochemical 
properties of the virus [7]. One such benefit of phage therapy 
circumscribes bactericidal traits, in which a bacterium infected with an 
obligately lytic phage is incapable of regaining viability [8]. Another 
benefit of phage therapy is auto-dosing: phages increase in number only 
where bacterial hosts are located; therefore, phage numbers are 
specifically dependent on bacterial count and host location, which 
extemporaneously allows for the propagation of an appropriate number 
of viral particles in the system predominantly in infected locations only. 
Furthermore, phages, when correctly purified, are deemed inherently non
-toxic for human administration purposes, albeit the release of bacterial 
toxins upon lysis remains a possibility, as is the case with cell-wall 
disrupting antibiotic compounds. Moreover, these viruses are known to 
have minimal disruption of normal flora, a narrower potential for 
eliciting resistance, along with an efficacy for biofilm clearance not seen 
in conventional antibiotic treatments. Phage particles are also much more 
easily discovered, with versatility in application form (e.g., liquids, 
creams, solids, etc.) representing a pharmacological benefit in phage 
therapy treatment development, as viral particle administration can even 
be combined with antibiotic compounds for improved efficacy in 
treatment success. Additional advantages for phage therapy include 
single-dose potentials, in which phage amplification is a singularly 
administered dose serving as a curative agent against a bacterial 
infection; phage transfer between subjects, when cross-infection may 
spread to other untreated individuals in a community; and phage 
administration efficacy, in which a small number of viral particles are 
needed for bacterial lysis. The implementation and administration of 
phage therapy thus has an immense amount of conspicuous benefits. 
      Yet, despite its long and successful Eastern European history, phage 
therapy remained unauthorized for routine use in human patients in the 
West until the late twentieth century, when the rise of antibiotic-resistant 
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) 
and multidrug-resistant Pseudomonas aeruginosa (MDRPA) created a 
need for phage research and application, as evidenced by the European 
Union’s $5.2 million contribution in 2013 to Phagoburn, the first large, 
multicentre clinical trial of bacteriophage therapy for human infections 
[9]. Such recognition of phage therapeutical significance was reinforced 
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the following year by the United States National Institute of Allergy and 
Infectious Diseases (NIAID), a center listing phage therapy and phage-
derived lysins as a vital constituent in its national approach against 
bacterial resistance in its 2014 strategic plan [10,11,12]. 
       This study specifically focuses on Staphylococcus aureus bacterial 
hosts and their respective viruses as a means to fight a variant strain of S. 
aureus, methicillin-resistant Staphylococcus aureus (MRSA), an 
antibiotic-resistant bacterial pathogen once again becoming a prominent 
re-emerging threat to global human health and well-being [13]. The 
bacterium, known to kill more Americans each year than HIV/AIDS, 
emphysema, Parkinson’s disease, and homicide combined [14,15,16], is 
a leading cause of nosocomial infections worldwide, causing over 
80,000 infections and 11,285 related deaths each year in the United 
States alone [17]. While invasive MRSA rates have declined in hospital-
based settings in the past decade [18], a prominent global emergence of 
community-associated MRSA (CA-MRSA), a strain characterized by its 
cutaneous infections in otherwise healthy individuals, has surfaced in 
non-clinical settings, causing skin and soft tissue infections, 
osteomyelitis, sepsis, endocarditis, toxic shock syndrome, along with 
necrotizing pneumonia [19,20,21]. CA-MRSA, a pathogen of epidemic 
proportions in the United States, has subsequently been non-
discriminatory in its selection of hosts, infecting high school, college, 
and professional athletes; men who have sex with men; military 
personnel; prison inmates; and children in day care centers [22]. 
Therefore, no group of individuals can be considered not at risk. 
Furthermore, a single clone of Staphylococcus aureus does not cause CA
-MRSA; rather, global CA-MRSA infections are the result of 
geographically divergent clones in which clonal replacement has been 
observed in numerous studies [23-28]. This large number of increasingly 
virulent and transmissible CA-MRSA clones dispersed around the world 
is a problem that is propagated by the fact that effective treatment for 
MRSA remains elusive and limited [29]. Thus, despite the recent 
availability of new antibiotics for Staphylococcus aureus [30], new and 
effective treatment options need to be explored as a means to efficiently 
treat antibiotic-resistant S. aureus strains well into the future [12]. One 
such naturally occurring treatment option is bacteriophage therapy, a 
promising solution to the worldwide MRSA epidemic.  
Staphylococcus aureus is a common bacterial strain that can be found in 
the nose, pharynx, perineum, axillae, and skin of humans. Persistent 
colonization of S. aureus and MRSA can be observed in approximately 
30% and 1.0%, respectively, of the United States population [31,32]. 
This commonplace nature of S. aureus serves as a foundation for 
studying Staphylococcus aureus and respective S. aureus bacteriophages 
in any local group in the United States. This study thus investigated the 
population of Coastal Carolina University (CCU), a higher educational 
institution situated in Conway, South Carolina. When taking into 
consideration the striking ubiquitous nature of bacteriophages in 
conjunction to the potential S. aureus reservoir amongst the CCU 
populace, Staphylococcus aureus bacteriophages were predicted to be 
prevalent on randomly sampled volunteers from CCU. In addition, 
Escherichia coli phage, or coliphage, populations were also investigated 
using the same samples provided by volunteers; the presence of 
coliphages are indicative of the presence of E. coli strains, of which 
serve as indicators not only of fecal contamination, but temporal 
competition to the commonly-found Staphylococcus aureus bacterial 
strains expected to colonize students. Thus, coliphage populations were 
simultaneously studied in conjunction with S. aureus phage populations 
on individual student volunteers.  
       Investigation of coliphage and S. aureus phage populations was 
conducted from 2014 to 2018. Over this five-year period, 225 randomly 
selected volunteers from Coastal Carolina University were swabbed 
behind ears and inside nasal capacities. Samples were filtered and 
amplified. Microbial tests were conducted in order to detect lytic 
activity, while molecular techniques were used in order to confirm the 
presence of specific bacteriophages. The purpose of this study was to 
address two questions about bacteriophages: does the Coastal Carolina 
University population contain bacteriophages that are lytic to 
Staphylococcus aureus and, if so, can these bacteriophages be isolated 
and identified based on polymerase chain reaction (PCR) techniques? 
Additionally, does the CCU community contain coliphages lytic to 
Escherichia coli, and can these phages be characterized via PCR 
analysis? 
       In addition to this sporadic study, a long-term pilot investigation 
into phage population fluctuations was initiated in 2017. Fifteen 
volunteers from Coastal Carolina University were randomly selected and 
sampled once a month from October of 2017 to March of 2018 in order 
to investigate coliphage and S. aureus phage population dynamics. The 
purpose of this pilot study was to provide a general understanding of 
bacteriophage population dynamics over an academic year, as 
fluctuations were informally noted in previous years but never 
quantified.  
 
Methods and Materials 
 
Collection and Filtration of Sporadic Samples 
Ear and nose samples were collected from 225 Coastal Carolina 
University volunteers over a five-year period from 2014 to 2018. Swabs 
were taken behind the ear and inside the nasal cavity for each volunteer. 
Swab samples were then placed in 1.5 mL microcentrifuge tubes 
(Carolina Biological Supply Company) containing 750 µL of phosphate 
buffer saline (PBS Tablets, Calbiochem), and were incubated at room 
temperature (25°C) for 30 minutes. Sterile filtration of PBS samples was 
performed using a 25 mm syringe filter with 0.2 µM PTFE membrane 
(VWR International) attached to a 10 mL syringe with Luer-Lok Tip 
(BD). PBS samples were filtered into sterile 1.5 mL microcentrifuge 
tubes.  
 
Collection of Long-Term Samples 
Fifteen (15) individuals from Coastal Carolina University volunteered 
samples on a monthly basis from October 2017 to March 2018. Swabs 
were taken from behind the ear and inside the nasal cavity; processing 
procedures were identical to those utilized during the sporadic study. 
Volunteers remained anonymous throughout the study and were given 
numbers as a means of identification. This pilot investigation was 
conducted in conjunction with the sporadic study. 
 
Amplification of Viral Particles 
Amplification of viral particles was conducted using both Escherichia 
coli B and Staphylococcus aureus cultures, and was performed via 
addition of 100 uL filtered sample to a 15 mL culture tube (Thermo 
Fisher) containing 3.0 mL of LB Miller broth (Sigma-Aldrich) and 200 
uL commercial Escherichia coli B (Carolina Biological Supply 
Company). Such amplification was repeated using commercially-




Plaque assays were prepared using sterile LB Miller broth and agar 
(Agar Grade A, BD) cell culture plates. Bacterial lawns were established 
on individual plates via addition of 75 µL of log-phase S. aureus liquid 
culture, of which was evenly distributed via a sterile spread plate 
technique. Spread plates were then incubated at 37°C for 30 minutes. 
Five microliters (5 µL) of amplified viral sample was added to three 
marked locations on a given plate, whilst 5 µL of PBS served as negative 
control for a fourth designated location on the plate. Amplified viral 
aliquots were dried for 10 minutes at 37°C. Plaque assays were then 
incubated overnight at 37°C. Analysis of plaque formation, if present, 
was conducted the following day. These plaque assay procedures were 
repeated using E. coli as bacterial host. 
 
DNA Extraction 
For viral capsid cleavage, 100 µL of amplified sample was placed into a 
sterile 1.5 mL microcentrifuge tube containing 10 µL of Proteinase K 
(ThermoFisher). Samples were vortexed and allowed to incubate for one 
hour at 37°C. Denaturation of Proteinase K enzymes was induced by 
placing samples in a heating block for 10 minutes at 95°C. Viral capsid 
cleavage was conducted for both S. aureus and E. coli samples. 
 
Polymerase Chain Reaction 
Polymerase chain reaction was conducted in a 50 uL reaction 
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volume consisting of 25 µL of GoTaq Green Master Mix (Promega 
Corporation), 21 µL of template (treated sample), and 4 uL of a 
respective primer set (See Table 1) to a 0.2 mL microcentrifuge tube 
(VWR International). PCR analysis was performed using a Bio-Rad 
Laboratories, Inc., MJ Mini Thermal Cycler. The thermocycler program 
comprised of an initial 4 minute DNA unwinding step at 95°C, followed 
by 39 cycles of 30 seconds at 94°C for DNA denaturation, 1 minute at 
55°C for primer annealing, and 72°C for 2 minutes for DNA extension. 
The final PCR product was then held at 4°C for temporary storage. PCR 
analysis was conducted for both S. aureus and E. coli phage samples. 
Coliphage primer sets included CPA, CPB, and CPO; S. aureus phage 
primer sets included SPA and SPB. 
 
Gel Electrophoresis and Gel Imaging 
Examination of both S. aureus and E. coli PCR products was then 
conducted using a 2% agarose gel (Agarose I, VWR) in 1x Tris-acetate-
EDTA (TAE) buffer solution. The gel was stained with 5 µL of ethidium 
bromide. Five (5 µL) of PCR product and 2 µL of 1 kb DNA ladder 
(Promega Corporation) was loaded to designated wells. The agarose gel 
was run for 60 minutes at 120 volts and then examined under UV light 
via the Molecular Imager ChemiDoc XRS+ Imaging System from Bio-
Rad Laboratories, Inc. 
 
Primers 
Individual primers such as K1F, 933, Micro, T4, HK, Mu, N4, JK, and 
Lambda that comprise coliphage primer sets CPA and CPB, as 
delineated in Table 1, were extracted from the 2009 UNC Chapel 
dissertation by Hee Suk Lee [33]. Primers ORF23 and ORF43 that 
constitute primer set CPO were developed by Dr. Paul E. Richardson’s 
lab at Coastal Carolina University. Primers such as 3A-Like, Twort-
Like, 11-Like, and 77-Like that comprise primer sets SPA and SPB were 
derived from R. Pantůček, et al. [34]. The 4 µL individual reaction for 
coliphage primer set CPA consisted of 0.2 µL HK Forward (“For”), 0.2 
µL HK Reverse (“Rev”), 0.2 µL 933For, 0.2 µL 933Rev, 0.2 µL T4For, 
0.2 µL T4Rev, 0.2 µL MicroFor, 0.2 µL MicroRev, 0.2 µL K1FFor, 0.2 
µL K1FRev, and 2 µL of nuclease-free water (Promega Corporation). 
The 4 µL individual reaction for coliphage primer set CPB consisted of 
0.22 µL MuFor, 0.22 µL MuRev, 0.22 µL Lambda For, 0.22 µL Lambda 
Rev, 0.22 µL JKFor, 0.22 µL JKRev, 0.22 µL N4For, 0.22 µL N4Rev, 
and 2.22 µL of nuclease-free water. The 4 µL individual reaction for 
coliphage primer set CPO consisted of 0.67 µL ORF23 For, 0.67 µL 
ORF23 Rev, 0.67 µL ORF43 For, 0.67 µL ORF43 Rev, and 1.33 µL of 
nuclease-free water. The 4 µL individual reaction for S. aureus primer 
set SPA consisted of 0.5 µL 3A-Like For, 0.5 µL 3A-Like Reverse, 0.5 
µL Twort Forward, 0.5 µL Twort Reverse, and 2.0 µL of nuclease-free 
water. The 4 µL individual reaction for S. aureus primer set SPB 
consisted of 0.5 µL 11-Like Forward, 0.5 µL 11-Like Reverse, 0.5 µL 





Sporadic Project: S. aureus phages 
From 2014 to 2018, an average of 42.9% of all Staphylococcus aureus 
plaque assays were observed to have indications of lytic activity (Table 
2). Positive S. aureus plaque assays ranged from 23.3% of all 30 
samples collected in 2014 to 66.7% of all 60 samples collected in 2017, 
with a standard deviation of 16.1%. Of the 225 samples collected over 
the designated five-year period, 21.8% and 45.3% of all S. aureus 
samples tested positive using molecular-based (PCR) and microbial-
based techniques, respectively. Positive PCR results ranged from 8.57% 
of all 35 samples in 2016 to 32.7% of all 30 samples collected in 2014, 
with a standard deviation of 10.8%. Of the total 102 lytic S. aureus 
plaque assays analyzed, only 48.0% could be characterized via the 
consensus sequence primers delineated in Table 1. 
 
Sporadic Project: E. coli phages 
From 2014 to 2018, an average of 36.8% of all Escherichia coli plaque 
assays were observed to have indications of lytic activity, as delineated 
in Table 3. Positive E. coli plaque assays ranged from 20.0% of all 45 
sporadic samples collected in 2018 to 51.7% of all 60 samples collected 
in 2017, with a standard deviation of 14.4%. Of the 225 samples 
collected from 2014 to 2018, 12.9% and 36.4% of all E. coli samples 
tested positive using PCR and microbial techniques, respectively. 
Positive PCR results ranged from 0.0% of all 35 samples in 2016 to 
36.7% of all 60 samples collected in 2017. Of the total 82 lytic E. coli 
plaque assays analyzed, only 35.4% could be characterized via 
consensus sequence primers represented in Table 1. 
 
Long-Term Project Pilot Study 
Immense fluctuations in both S. aureus and E. coli phages were 
observed between October 2017 and March 2018 (Figures 1-2). The 
greatest number (N) of positive S. aureus phage samples were 
predominantly observed in the months of October (NSE=13, NSN=14, 
Figure 1; NSE=5, NSN=4, Figure 2) and November (NSE=5, NSN=6, Figure 
1; NSE=1, Figure 2), after which the local S. aureus phage population 
staved off to zero for both nose and ear samples while the local 
coliphage population upsurged in February (NCE=2, NCN=2, Figure 1; 
NCE=0, NCN=3, Figure 2) and March (NCE=5, NCN=1, Figure 1; NCE=7, 




The Coastal Carolina University population was found to contain 
bacteriophages lytic to Staphylococcus aureus, as is indicated by an 
average of 45.3% of all S. aureus plaque assays showing positive lytic 
activity (Table 2) in plague assays. Yet, of these 102 lytic S. aureus 
assays, only 49 samples (48.0%) were identified via PCR analysis. All 
49 samples were classified as 77-Like phages; no other characterizations 
such as 3A-Like, 11-Like, or Twort-Like were discerned. Such a 
disparity in molecular phage identification can be attributed to the S. 
aureus primer sets used: primer sets SPA and SPB, as extracted from R. 
Figure 2. Summary of positive coliphage ear (CE), coliphage nose 
(CN), S. aureus phage ear (SE), and S. aureus phage nose (SN) 
plaque assays from October 2017 to March 2018 in long- term pilot 
study. No long-term data collected for January 2018. 
Figure 1. Summary of positive coliphage ear (CE), coliphage nose 
(CN), S. aureus phage ear (SE), and S. aureus phage nose (SN) PCR 
samples from October 2017 to March 2018 in long-term pilot study. 
No long-term data collected for January 2018. 
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Primer Name Primer Size 
(bp) Primer Sequences (5’ to 3’) 
 CPA 
Podoviridae CKV1F, gp34 2110 
K1FFor 16 TGGAAGCCCGTGAGAC  
K1FRev 18 GCAGCGTCAATCGCTCGG  
Podoviridae 933Wp09, hkaG 
gene 488 
933For 18 GCAATACATCAAACGCCG  
933Rev 16 GCGAATGCCAGCGGCG  
Microviridae Hypothetical 
protein 1039 
MicroFor 25 GCTGCCGTCATTGCTTATTATGTTC  
MicroRev 25 GYTAYCGBMMCATYAAYTAHTCACG  
Myoviridae Major head protein 
(gene 23) 704 
T4setFor 20 GATATTTGTGGYGTTCAGCC 
T4setRev 24 GTCAAATACACCAGCTTTAGAACC  
Siphoviridae cII protein 177 
HKsetFor 20 CACAGCGAGAAATTGATCGC 
HKsetRev 19 CTAATCGGACTGATGTCTG  
CPB 
Myoviridae Tail fiber gene 
(MUP49) 171 
MusetFor 21 GAAAACGACTCAATCCTTGCC  
MusetRev 20 TCATCAGGTCTTTTGTTGTGG  
Podoviridae Hypothetical 
protein  2285 
N4For 20 GCACATGCAGAATAAGGTTG  
N4Rev 20 CCATTAGTAACACCATCTGC  
Siphoviridae Tail fiber protein  878 
JKsetFor 16 GYGAYCAGATGGTTCC  
JKsetRev 16 CAATRTCYTCYTARTTG  
Siphoviridae B gene  307 
LambdaFor 20 TGGGCGTACTTTATGGGGCG  








ORF23For 20 TGGCGCAGTAACTCAGATTG  




(DNA polymerase) 198 
ORF43For 20 CCCTGCGCCTTTCATAATAA  
ORF43Rev 20 ATCGCAGGAACAGCTCCTAA  
SPA 
3A-like phages Tail Fibers 744 
3A-like For 20 TATCAGGCGAGAATTAAGGG  





Twort-like For 20 TGGGCTTCATTCTACGGTGA  
Twort-like Rev 23 GTAATTTAATGAATCCACGAGAT  
SPB 
11-like phages Hypothetical tail 
proteins 405 
11-like For 22 ACTTATCCAGGTGGCGTTATTG  
11-like Rev 23 TGTATTTAATTTCGCCGTTAGTG  
77-like phages Hypothetical tail 
proteins 155 
77-like For 19 CGATGGACGGCTACACAGA  
77-like Rev 23 TTGTTCAGAAACTTCCCAACCTG  
Table 1. Summary of primer sets used. Primers comprising primer sets SPA and SPB were extracted from R. Pantůček, et al. 
[34]. Primers comprising primer sets CPA and CPB were derived directly from the work of Hee Suk Lee [33]. Primer set CPO 
was developed by Dr. Paul E. Richardson, the principal investigator (PI) of this study. 
 Year # of Samples 
# of Positive  
S. aureus 
Microbial Tests 





S. aureus Positive 
Molecular Tests 
% of Positive 
S. aureus Molecular 
Tests 
 2014  30 7 23.3% N/A* N/A* 
2015 55 21 38.2% 18 32.7% 
2016 35 17 48.6% 3 8.57% 
2017 60 40 66.7% 18 30.0% 
2018 45 17 37.8% 10 22.2%  
Total 225 102 45.3% 49 21.8% 
Yearly Average 45 20.4 42.9% 12.25 23.4% 
Table 2. Sporadic project summary of S. aureus microbial (plaque assay) and molecular (PCR) results by 
year. *Molecular tests were not conducted during the 2014 study year. 
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Pantůček, et al., consisted of conserved genomic sequences characteristic 
only of S. aureus phage types 3A, 11, 77, and Twort, of which are 
representative of bacteriophage serogroups A, B, F, L, and D. 
Serogroups A, B, and F comprise temperate phages that may enter a lytic 
cycle in favorable environmental conditions, and thus may only prove 
useful in S. aureus phages that make use of both lysogenic and lytic 
cycles. This study, it must be noted, principally focused on phages lytic 
to Staphylococcus aureus, albeit temperate phages were simultaneously 
characterized via PCR analysis, as well, as many non-lytic S. aureus 
samples were shown to be positive for lysogenic strains. Furthermore, S. 
aureus primer sets derived from R. Pantůček, et al., only represent five 
out of the eleven S. aureus phage serogroups [35]. Thus, the fact that 
only 48.0% of all lytic S. aureus plaque assay samples could be 
identified and characterized via PCR analysis may be due to utilizing 
primer sets unrepresentative of every Staphylococcus aureus phage 
serotype. Another speculation may be that the S. aureus phage human 
reservoir has yet to be thoroughly explored, as only around 250 
staphylococcal bacteriophages have ever been described in literature; 
likewise, S. aureus phages that have thus far been characterized, in turn, 
were determined to have high diversity and mosaicism in genomic 
constitution resulting from recombination and horizontal transfer of 
sequences [34]. Thus, the S. aureus phage reservoir appears to be not 
only rich in the number of clandestine lytic constituents, but potentially 
abundant in a diverse repository of staphylococcal phages yet to be 
characterized. Exploration of novel primers may improve such molecular 
phage characterization, and thus provide improved insight into the depth 
of the S. aureus phage cistern and its promising utility against 
Staphylococcus aureus and its antibiotic resistant variants. 
As aforementioned, an average of 42.9% of all S. aureus plaque assays 
had indications of lytic activity. Assuming automatic phage presence 
amongst naturally-occurring S. aureus colonies in human populations, 
this statistic generally coincides with the data published by the American 
College of Physicians (ACP) of which, using extrapolated data, 
predicted Staphylococcus aureus cultures colonize around 31.6% of 
individuals in the United States [38]. This study focused on the 
university population of individuals living in an environment comprised 
of a stressful atmosphere and a higher population density, of which may 
contribute to an inflation in the human community phage reservoir. A 
more pronounced phage population, in turn, can be attributed to stress-
related immunosuppression, stress-induced susceptibility to bacterial 
infections, and therefore elevated phage production and increased phage 
detection rates. 
Analogously, of the 82 lytic E. coli plaque assays analyzed, only 35.4% 
could be identified and characterized via PCR analysis (Table 3). Such a 
divergence may also be attributed to the primer sets used, as CPA, CPB, 
and CPO primer sets represent somatic coliphages belonging to the 
following taxonomic families: Podoviridae, Microviridae, Myoviridae, 
and Siphoviridae, along with ICTV type T4, of which represents its own 
group. The discrepancy in molecular identification of lytic coliphages 
could therefore be associated with primer sets that appear inadequate in 
representing the extremely diverse group of somatic coliphages.  
A reservoir of coliphages appears to be prominent amongst the Coastal 
Carolina University human population, as 36.8% of all volunteers 
sampled between 2014 and 2018 were found to be positive for 
coliphages (Table 3). Forty-five percent (45%) of all positive PCR 
products were detected using the CPO primer set, of which includes 
primers ORF 23 and ORF 43 that encode a major capsid protein and T-
even DNA polymerase enzyme, respectively. Fifty-five percent (55%) of 
all positive coliphage PCR products were identified via CPA and CPB 
primer sets. Such discrepancy can be described in terms of the 
specificity of the target genes of primer sets: the CPO primer set targets 
highly conserved T-even phage consensus sequences encoding the T-
even DNA polymerase and a T-even major capsid protein. Primer sets 
CPA and CPB, originally derived from the work of Hee Suk Lee, were 
developed for the purpose of optimizing group-specific PCR detection of 
coliphage families that were predominantly found in fecal contaminated 
water settings [33]. Local coliphage detection via utilization of primer 
set CPO has been confirmed by Cannon, et al., [36], while coliphage 
detection using CPA and CPB has been confirmed in Chapel Hill, North 
Carolina, an area relatively close in distance and climate to Coastal 
Carolina University [33]. Such identification of phages in diverse 
locations suggests that sampled bacteriophages appear widely 
distributed, as members of identified taxonomic groups using specific 
primer sets CPA, CPB, and CPO have not only been found in water 
sources, as suggested by Cannon, et al. [36], and Lee [33], but also 
amongst the human population, as confirmed and delineated by this 
study. Transportation schemes of coliphages between water sources, 
fecal matter, and the human population remain unknown and 
unquantified, albeit the presence of coliphages remains to be viewed as 
an indicator of fecal contamination.  
The immense profusion of coliphages amongst the Coastal Carolina 
University population may be the result of relatively high population 
density and stress-induced immunosuppression, of which may increase 
susceptibility to bacterial infection and thus elevate localized phage 
production. Most notably, coliphages can serve as indicator species of 
fecal contamination, as aforementioned, and therefore may represent 
individual hygiene level at a given moment of time, and possibly 
susceptibility to bacterial colonization and thus phage proliferation. 
The long-term study circumscribing bacteriophage population 
fluctuations strove to quantify primordial trends observed in local S. 
aureus and E. coli phage population dynamics. Staphylococcus aureus 
bacteriophage numbers were observed to be greatest in number in 
October of 2017, after which positive S. aureus sample numbers for both 
molecular (Figure 1) and microbial (Figure 2) tests declined. No positive 
PCR products were observed for coliphage samples from October 2017 
to December 2017, albeit 4 positive coliphage PCR products were 
Year  # of Samples 
# of Positive E. 
coli Microbial 
Tests 
% of Positive 
E. coli Microbial 
Tests 
# of 
E. coli Positive  
Molecular 
Tests 
% of Positive 
E. coli Molecular 
Tests 
 2014  30 12  40.0% N/A* N/A* 
2015 55 13 23.6% 7 12.7% 
2016 35 17 48.6% 0 0.0% 
2017 60 31 51.7% 22 36.7% 
2018 45 9 20.0% 0 0.0%  
Total 225 82 36.4% 29 12.9% 
Yearly Average 45 16.4 36.8% 7.25 12.4% 
Table 3. Sporadic project summary of E. coli microbial (plaque assay) and molecular (PCR) results by year. 
*Molecular tests were not conducted during the 2014 study year. 
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observed starting in February of 2018. In March 2018, the last month of 
observation, 6 positive coliphage molecular samples were detected. A 
few positive coliphage plaque assays were observed from October 2017 
through December 2017, albeit a tremendous escalation in positive 
samples was seen around February of 2018 (Figure 2). This small pilot 
study illustrated the prospective notion that coliphage occupancy is 
capable of representing temporal competition to Staphylococcus aureus 
phages (and vice versa), as S. aureus phage populations appear to 
decline while coliphage populations tend to escalate, as can be visualized 
by both Figure 1 and Figure 2. Furthermore, this pilot study provided 
insight into local phage population fluctuations, of which could also 
potentially be attributed to external factors such as UV exposure, 
physiological and biological stress, mechanical damage, along with the 
utilization of various skin products such as acne treatments and sun 
block.  
Conclusion 
Plaque assay results for both coliphage and S. aureus phage sporadic 
studies signify that broad detection of bacteriophages appears best with 
microbial techniques, albeit molecular methods remain valuable for 
sensitive detection of both lytic and lysogenic phages. Results indicated 
that an extensive lytic bacteriophage reservoir against Staphylococcus 
aureus can be found in the general populace of Coastal Carolina 
University, albeit the local S. aureus phage population remains dynamic 
in nature and appears to fluctuate immensely for unknown but 
speculative reasons. With the growing antibiotic resistant community-
associated MRSA threat, harvesting and exploring the utility of 
bacteriophages, the natural bactericidal products crafted by billions of 
years of evolution, may prove to be immensely useful to humanity as a 
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